Çѱ¹´ëÇнŹ® Ȩ > ´º½º > Çмú/¼¼¹Ì³ª

¸ñ·Ï
ÇÁ¸°Æ® ½ºÅ©·¦
Àü³²´ë ´ëÇпø»ý, Ú¸ Àú¸í Àú³Î Ç¥Áö³í¹® ¼±Á¤
¹Ú¼±ÇϾ¾, ¼¼°è »óÀ§ 10% <¾à¹°´ë»ç ¹× ¼Ò½Ç> 5¿ùÈ£¿¡
Àü³²´ë ´ëÇпø»ýÀÇ ³í¹®ÀÌ ±¹Á¦Àú¸íÇмúÁö Ç¥Áö³í¹®À¸·Î ¼±Á¤µÅ È­Á¦´Ù.

Àü³²´ë´Â ÀÌ ´ëÇÐ ¹Ú¼±ÇÏ(»ý¹°°úÇлý¸í±â¼úÇаú ¹Ú»ç°úÁ¤ 1³â)¾¾°¡ ÁÖÀúÀÚ·Î Âü¿©ÇÑ ¿¬±¸³í¹®ÀÌ ¼¼°è »óÀ§ 10%¿¡ ¼ÓÇÏ´Â ¹Ì±¹ °úÇÐÀú³Î <¾à¹°´ë»ç ¹× ¼Ò½Ç(Drug Metabolism and Disposition)> 5¿ùÈ£ Ç¥Áö¿¡ °ÔÀçµÆ´Ù°í 30ÀÏ ¹àÇû´Ù.

¹Ú ¾¾ÀÇ ³í¹®ÁÖÁ¦´Â ¡®Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation¡¯À¸·Î »ç¶÷ÀÇ ¾à¹°´ë»ç¿¡ Áß¿äÇÑ È¿¼ÒȰ¼ºÀ» ¹Ì»ý¹° È¿¼Ò¿¡¼­ °³¹ß, ½Å¾à°³¹ß°úÁ¤¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿¬±¸·Î Æò°¡¹Þ°í ÀÖ´Ù. ³í¹®Àº ¹Ú ¾¾°¡ ¼®»ç°úÁ¤ µ¿¾È ¼öÇàÇÑ ¿¬±¸°á°úÀ̸ç, Áö³­ÇØ 6¿ù ÀϺ» ¿ÀŰ³ª¿Í¿¡¼­ °³ÃÖµÈ ±¹Á¦ÇÐȸ¿¡¼­ ±¸µÎ·Îµµ ¹ßÇ¥µÈ ¹Ù ÀÖ´Ù.

<¾à¹°´ë»ç ¹× ¼Ò½Ç>Àº ¹Ì±¹ ¾à¸®ÇÐ ¹× ½ÇÇè¿ä¹ý ÇÐȸ(American Society for Pharmacology and Experimental Therapeutics)°¡ 1973³âºÎÅÍ ¹ß°£ÇÑ °úÇÐÀú³Î·Î ½Å¾à°³¹ß, ¾à¹°´ë»ç ¹× °ü·Ã È¿¼Òµé¿¡ ´ëÇÑ Çмú°á°ú¸¦ ¹ßÇ¥ÇÏ´Â ±¹Á¦ Àú¸íÇмúÁö´Ù.
¹ÎÇöÈñ ±âÀÚ (mhhph@unn.net) | ÀÔ·Â : 10-04-30 ¿ÀÀü 10:25
¨Ï Çѱ¹´ëÇнŹ®(http://unn.net) ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö | ÀúÀ۱ǹ®ÀÇ
¸ñ·Ï
ÇÁ¸°Æ® ½ºÅ©·¦
ÀÌ ¸§ ³» ¿ë ºñ¹Ð¹øÈ£

1

ÃֽŠÆ÷Åä´º½º